• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    IMC Announces Results of its Annual General and Special Meeting of Shareholders

    8/3/21 7:30:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $IMCC alert in real time by email

    TORONTO, ON and GLIL YAM, ISRAEL / ACCESSWIRE / August 3, 2021 / IM Cannabis Corp. ("IMC" or the "Company") (CSE:IMCC), (NASDAQ:IMCC), a multi-country operator ("MCO") in the medical and adult-use recreational cannabis sector with operations in Israel, Germany and Canada, is pleased to announce the voting results from its annual general and special meeting of shareholders held on Wednesday July 28, 2021 (the "Meeting").

    A total of 37,108,584 common shares of the Company were voted at the Meeting, representing 65.03% of the Company's issued and outstanding common shares as of the date of the Meeting. Shareholders voted to approve all matters brought before the Meeting including fixing the number of directors, the election of all director nominees, the re-appointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global as auditors for the ensuing year and the Company's stock option plan.

    Detailed results of the votes on the election of directors are as follows:

    Director Nominee

    Votes For

    %

    Votes Withheld

    %

    Oren Shuster

    26,398,764

    96.19

    1,045,449

    3.81

    Marc Lustig

    26,398,755

    96.19

    1,045,458

    3.81

    Vivian Bercovici

    27,440,895

    99.99

    3,318

    0.01

    Haleli Barath

    27,441,054

    99.99

    3,159

    0.01

    Brian Schinderle

    27,440,784

    99.99

    3,429

    0.01

    For further detailed voting results on the Meeting, please refer to the Company's Report of Voting Results filed on SEDAR at www.sedar.com.

    About IM Cannabis Corp.

    IMC is an MCO in the medical and adult-use recreational cannabis sector, headquartered in Israel and with operations In Israel, Germany and Canada. Over the past decade, the Company believes that the IMC brand has become synonymous with quality and consistency in the Israeli medical cannabis market. The Company has also expanded its business to offer intellectual property-related services to the medical cannabis industry.

    In Europe, IMC operates through Adjupharm GmbH, a German-based subsidiary and EU-GMP-certified medical cannabis distributor. IMC's European presence is augmented by strategic alliances with various pan-European EU-GMP cultivators and distributors to capitalize on the increased demand for medical cannabis products in Europe and bring the IMC brand and its product portfolio to European patients.

    In Canada, IMC operates through Trichome d/b/a JWC. JWC is a licensed producer located in Kitchener, Ontario, selling cannabis flower, pre-rolls, hash and kief in the Canadian recreational cannabis market under the JWC and WAGNERS brands. JWC operates with high standards for providing clean, consistent, aeroponically-grown premium cannabis products to medical patients and the adult-use market throughout Canada and the world. IMC also operates MYM Nutraceuticals Inc. and its licensed producer subsidiary, Highland Grow Inc.

    CONTACTS:

    Oren Shuster
    CEO, IM Cannabis Corp.
    +972-77-3603504
    [email protected]

    Caitlin Kasunich
    Media Relations - U.S.
    +1 212-896-1241
    [email protected]

    Gal Wilder
    Media Relations - Canada
    +1 416-602-4092
    [email protected]

    Elizabeth Barker
    Investor Relations
    +1 212-896-1203
    [email protected]

    SOURCE: IM Cannabis Corp.



    View source version on accesswire.com:
    https://www.accesswire.com/658135/IMC-Announces-Results-of-its-Annual-General-and-Special-Meeting-of-Shareholders

    Get the next $IMCC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMCC

    DatePrice TargetRatingAnalyst
    10/5/2021$8.00Buy
    ROTH Capital
    7/14/2021Buy
    Desjardins
    7/14/2021$10.50Buy
    Desjardins
    More analyst ratings

    $IMCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IM Cannabis Reports Third Quarter 2025 Financial Results

    TORONTO and GLIL YAM, Israel, Nov. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC), an international medical cannabis company, announced its financial results today for the third quarter and nine months ended September 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter and nine months ended September 30, 2024, unless otherwise stated. Q3 2025 Financial Highlights:  Consistent Revenue for Q3 2025 and 2024 of $13.9 million.13% Gross profit decrease vs. Q3 2024 of $2.7 million vs. $3.1 million.13% Gross Margin decrease vs. Q3 2024 of 20% vs. 23%. $3.1 million One time goodwill and intangible asset impairment in Q3 2025 Operating

    11/13/25 9:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Announces CFO Departure

    TORONTO and GLIL YAM, Israel, Oct. 29, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ:IMCC) (the "Company", "IM Cannabis", or "IMC"), a leading international medical cannabis company with operations in Israel and Germany, today announced that Uri Birenberg, the Company's Chief Financial Officer, will be stepping down from his role  for personal reasons. Mr. Birenberg is expected to continue serving as Chief Financial Officer until January 5, 2026, or such earlier date as may be determined by the Company, and will assist in a structured transition process until a successor is appointed. Oren Shuster, Chief Executive Officer of IMC, said, "On behalf of our entire team, I would like to thank U

    10/29/25 4:01:00 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Signs Non-Binding Term Sheet to Acquire 60% Stake in Innovative Quantum Computing Bio Data Company for Up to $54 Million

    TORONTO and GLIL YAM, Israel, Oct. 23, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced the signing of a non-binding indicative term sheet for a proposed securities exchange agreement to acquire a 60% equity interest in a pioneering quantum computing bio data company ("The Target Company") for aggregate consideration of up to $54 million. The Target Company specializes in utilizing quantum computing principles to store, manipulate, and analyze BIO data more efficiently than current technologies, offering groundbreaking advancements in biological data processing and analyti

    10/23/25 9:11:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH Capital initiated coverage on IM Cannabis with a new price target

    ROTH Capital initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $8.00

    10/5/21 7:57:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    Desjardins initiated coverage on IMC Mortgage Co

    Desjardins initiated coverage of IMC Mortgage Co with a rating of Buy

    7/14/21 8:40:32 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    Desjardins initiated coverage on IM Cannabis with a new price target

    Desjardins initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $10.50

    7/14/21 7:01:53 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    SEC Filings

    View All

    SEC Form 6-K filed by IM Cannabis Corp.

    6-K - IM Cannabis Corp. (0001792030) (Filer)

    11/17/25 6:05:54 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by IM Cannabis Corp.

    6-K - IM Cannabis Corp. (0001792030) (Filer)

    11/13/25 9:16:06 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by IM Cannabis Corp.

    6-K - IM Cannabis Corp. (0001792030) (Filer)

    11/6/25 7:17:01 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Financials

    Live finance-specific insights

    View All

    IM Cannabis Reports Third Quarter 2025 Financial Results

    TORONTO and GLIL YAM, Israel, Nov. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC), an international medical cannabis company, announced its financial results today for the third quarter and nine months ended September 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter and nine months ended September 30, 2024, unless otherwise stated. Q3 2025 Financial Highlights:  Consistent Revenue for Q3 2025 and 2024 of $13.9 million.13% Gross profit decrease vs. Q3 2024 of $2.7 million vs. $3.1 million.13% Gross Margin decrease vs. Q3 2024 of 20% vs. 23%. $3.1 million One time goodwill and intangible asset impairment in Q3 2025 Operating

    11/13/25 9:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Announces Warrant Amendments and Form F-3 Resale Registration Statement Filing

    TORONTO and GLIL YAM, Israel, Aug. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ:IMCC), a leading medical cannabis company with operations in Israel and Germany, announces that it has agreed with holders (each, a "Holder") of common share purchase warrants ("November 2024 Warrants") issued by the Company as part of its non-brokered private placement offering which closed on November 12, 2024 to: (x) reduce the exercise price of each November 2024 Warrant from C$4.32 to C$3.43; and (y) extend the expiration date of each November 2024 Warrant from November 12, 2026 to July 31, 2030 (together, the "Transaction"). Form F-3 Resale Registration Statement The

    8/13/25 4:01:00 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Reports Second Quarter 2025 Financial Results

    IMC Delivers Strong Profit and Margin Growth Despite Revenue Impact from External Challenges in Q2 2025 TORONTO and GLIL YAM, Israel, Aug. 12, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC), an international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter ended June 30, 2024, unless otherwise stated. Q2 2025 Financial Highlights   14% Revenue decrease vs. Q2 2024 of $12.7M vs. $14.8M  306% Gross profit increase vs.

    8/12/25 8:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by IM Cannabis Corp.

    SC 13G - IM Cannabis Corp. (0001792030) (Subject)

    2/21/23 10:56:41 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by IM Cannabis Corp. (Amendment)

    SC 13D/A - IM Cannabis Corp. (0001792030) (Subject)

    2/8/23 1:29:15 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by IM Cannabis Corp. (Amendment)

    SC 13G/A - IM Cannabis Corp. (0001792030) (Subject)

    2/2/23 10:38:01 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Leadership Updates

    Live Leadership Updates

    View All

    IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors

    TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ --  IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC) (CSE:IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company's board of directors (the "Board") effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company's commitment to driving growth while focusing on sustainable profitability. "We are thrilled to welcome Shmulik to our Board of Directors," said Oren Shuster, Chief Executive Officer of

    9/11/24 8:30:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Announces the appointment of Uri Birenberg as Chief Financial Officer

    TORONTO and GLIL YAM, Israel, Oct. 10, 2023 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Uri Birenberg will join the company's leadership team as Chief Financial Officer effective October 10, 2023.  This appointment strengthens IMC's financial leadership and strategic direction for achieving sustainable profitability. "We're delighted to welcome Uri as our new Chief Financial Officer at IMC. His impressive track record and extensive experience with large scale international organizations, as well as with startups, make him an outstandin

    10/10/23 7:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Corp. Appoints Rinat Efrima as New Chief Executive Officer of IMC Holdings, the Company's Israeli Subsidiary

    Oren Shuster remains Chief Executive Officer and Director of IM Cannabis Corp.; other managerial changes include the promotion of Yael Harrosh to Chief Legal and Operations Officer of IM Cannabis Corp.TORONTO, ON and GLIL YAM, ISRAEL / ACCESSWIRE / January 13, 2022 / IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE:IMCC)(NASDAQ:IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany today announced the appointment of Rinat Efrima as the new Chief Executive Officer of IMC Holdings Ltd. ("IMC Holdings"), the Company's wholly-owned Israeli subsidiary. Ms. Efrima will join the Company in the first quarter of 2022. In addition, Ya

    1/13/22 8:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care